Scholar Rock Holding Corporation Common Stock (SRRK)

Price$44.30

Value ScoreF

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-7.38%

Price vs S&P 500 (4W)-8.44%

VGM Score33.16

Market Capitalization$5.31B

All Metrics

Book Value / Share (Quarterly)$2.32

P/TBV (Annual)3.25x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.55

Price vs S&P 500 (YTD)-7.59%

Net Profit Margin (TTM)-236.96%

EPS (TTM)$-3.45

10-Day Avg Trading Volume1.27M

EPS Excl Extra (TTM)$-3.45

EPS (Annual)$-2.47

ROI (Annual)-58.81%

Net Profit Margin (5Y Avg)-1236.36%

Cash / Share (Quarterly)$4.03

ROA (Last FY)-51.86%

EBITD / Share (TTM)$-3.42

ROE (5Y Avg)-60.37%

Operating Margin (TTM)-231.80%

Cash Flow / Share (Annual)$-2.77

P/B Ratio19.23x

P/B Ratio (Quarterly)21.21x

Net Income / Employee (Annual)$-852,200

EV / Revenue (TTM)107.28x

Net Interest Coverage (TTM)-809.50x

ROA (TTM)-96.29%

EPS Incl Extra (Annual)$-2.47

Current Ratio (Annual)6.95x

Quick Ratio (Quarterly)8.41x

3-Month Avg Trading Volume1.36M

52-Week Price Return29.34%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.98

P/S Ratio (Annual)159.94x

Asset Turnover (Annual)0.09x

52-Week High$52.19

Operating Margin (5Y Avg)-1238.26%

EPS Excl Extra (Annual)$-2.47

CapEx CAGR (5Y)-31.83%

Tangible BV CAGR (5Y)36.11%

26-Week Price Return0.54%

Quick Ratio (Annual)6.68x

13-Week Price Return-4.01%

Total Debt / Equity (Annual)0.41x

Current Ratio (Quarterly)8.64x

Enterprise Value$5.07B

Asset Turnover (TTM)0.16x

Book Value / Share Growth (5Y)-21.57%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-405.24%

Cash / Share (Annual)$3.39

3-Month Return Std Dev55.96%

Net Income / Employee (TTM)$-1,408,800

ROE (Last FY)-66.81%

EPS Basic Excl Extra (Annual)$-2.47

Receivables Turnover (TTM)1.23x

Total Debt / Equity (Quarterly)0.71x

EPS Incl Extra (TTM)$-3.45

ROI (TTM)-112.67%

P/S Ratio (TTM)112.23x

Pretax Margin (5Y Avg)-1236.36%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$5.04

Price vs S&P 500 (52W)4.98%

Year-to-Date Return0.57%

5-Day Price Return-6.52%

EPS Normalized (Annual)$-2.47

ROA (5Y Avg)-41.66%

Net Profit Margin (Annual)-405.24%

Month-to-Date Return-10.14%

Cash Flow / Share (TTM)$-1.95

EBITD / Share (Annual)$-2.51

Operating Margin (Annual)-404.85%

LT Debt / Equity (Annual)0.41x

ROI (5Y Avg)-50.42%

LT Debt / Equity (Quarterly)0.71x

EPS Basic Excl Extra (TTM)$-3.45

P/TBV (Quarterly)5.05x

P/B Ratio (Annual)18.30x

Pretax Margin (TTM)-236.96%

Book Value / Share (Annual)$2.26

Price vs S&P 500 (13W)-12.26%

Beta0.72x

P/FCF (Annual)230.00x

Revenue / Share (TTM)$0.00

ROE (TTM)-162.89%

52-Week Low$27.07

vGradeF

mGradeC

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.83est. -0.82

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.36

4.35

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	$44.30
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

Scholar Rock is a biopharmaceutical company developing treatments for rare neuromuscular diseases, with a focus on Spinal Muscular Atrophy. Its lead candidate, apitegromab, is in clinical development with both intravenous and subcutaneous formulations. The company's pipeline also includes SRK-439, a myostatin inhibitor in development for rare neuromuscular indications.